Trial
NCT02200562
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
—
Condition
Stage III or IV Melanoma
Intervention
ipilimumab and dabrafenib
Why stopped
BMS withdrew support and required this trial to stop enrolling; Phase II portion never began, only a Phase I trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-01